Small Biomaterials

Lung‐Targeting Interleukin‐10 mRNA Sulfonium Lipid Nanoparticles Ameliorate Acute Lung Injury

Yuqin Men, David O. Popoola, Yuqi Song, Zhi Cao, Robert Gardner, Rezwana Karim, Chunyan Wang, Nathan Tucker, Robert Cooney, Qinghe Meng, Yamin Li
Wiley · 2026-11-20 · DOI 10.1002/smll.76758

Abstract

ABSTRACT Acute respiratory distress syndrome (ARDS) is the most severe manifestation of acute lung injury (ALI), characterized by diffuse pulmonary inflammation, impaired gas exchange, and high morbidity and mortality. Despite the clinical significance of ARDS, no effective pharmacological therapies are currently available. In this study, we developed a lung‐targeted mRNA‐sulfonium lipid nanoparticle (mRNA/sLNP) delivery system for the treatment of ALI/ARDS in a mouse model. We first examined different heads and tails to optimize sulfonium lipid structure, leading to the identification of a top‐performing HOSEH formulation. HOSEH sLNP was comprehensively characterized and subsequently loaded with interleukin‐10 (IL‐10) mRNA, an immunomodulatory cytokine with potent anti‐inflammatory activity. As a proof‐of‐concept, in a lipopolysaccharide (LPS)‐induced ALI mouse model, IL‐10 mRNA/sLNP demonstrated both prophylactic and therapeutic efficacy, significantly attenuating pulmonary and systemic inflammation, restoring alveolar‐capillary barrier integrity, and reducing lung tissue damage. These findings highlight the potential of lung‐targeted mRNA therapeutics in inflammatory lung diseases. With further development, IL‐10 mRNA/sLNP may represent a promising strategy for the treatment of ALI and ARDS.

Read at publisher →